Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Neurogene Inc.
NGNE · SEC Filings
website
131
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and the...
Price
26
Market Cap
410.86 M
Float
12.54 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about NGNE
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Neurogene Inc.
NGNE · SEC Filings
12.54 M
Float
26
Price
410.86 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
NEW
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 9, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 24, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 13, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2025
News
TYPE
HEADLINE
FILED AT
8-K
NEW
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Updates for NGN-401
Nov 9, 2026
8-K
Neurogene Reports Second Quarter 2026 Financial Results and Provides Update on NGN-401 Rett Syndrome Program
Aug 11, 2026
8-K
Neurogene Inc. Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Jul 1, 2026
8-K
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Jun 29, 2026
8-K
Neurogene Completes Dosing in Embolden™ Registrational Trial for NGN-401
Jun 8, 2026
8-K
Neurogene Inc. Announces Results of 2026 Annual Meeting of Stockholders
Jun 4, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
Jul 1, 2026
424B5
PENDING FIXED PRICE OFFERING | Bank: Leerink Partners
Jun 30, 2026
424B5
August 2025 ATM
Aug 11, 2025
424B3
UPDATED | SHARE RESALE REGISTRATION | Shares amount: 4,000,042 | Warrants amount: 2,165,042
Apr 1, 2025
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]
Dec 18, 2024
425
Registration
Dec 6, 2023
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 24, 2026
S-3
March 2025 SHELF
Mar 24, 2025
POS AM
Form POS AM - Post-Effective amendments for registration statement
Mar 24, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 24, 2025
S-1
INITIAL REGISTRATION FOR OFFERING EFFECTIVE
Dec 2, 2024
S-8
Registration
Feb 20, 2024
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 16, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 16, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 25, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 26, 2024
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G
PRUDENTIAL FINANCIAL INC (Filed by)
Oct 7, 2026
SCHEDULE 13G
JENNISON ASSOCIATES LLC (Filed by)
Oct 6, 2026
4
McMinn Rachel (Reporting)
Oct 2, 2026
SCHEDULE 13G/A
Redmile Group, LLC (Filed by)
Aug 14, 2026
SCHEDULE 13G/A
Trails Edge Capital Partners, LP (Filed by)
Aug 14, 2026
SCHEDULE 13G
BALYASNY ASSET MANAGEMENT L.P. (Filed by)
Aug 14, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Apr 7, 2025
CORRESP
Form CORRESP - Correspondence
Apr 2, 2025
LETTER
Form UPLOAD - SEC-generated letter
Mar 31, 2025
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 31, 2025
EFFECT
Form EFFECT - Notice of Effectiveness
Dec 17, 2024
CORRESP
Form CORRESP - Correspondence
Dec 12, 2024
